MP Biomedicals announces the launch of advanced gastrointestinal diseases diagnostic kits

FHS
August 27, 2024
11:17 am

MP Biomedicals completes its range of in vitro diagnostic tests for infectious diseases with new immunochromatographic-based qualitative rapid tests.The new diagnostic kits by MP Biomedicals leverage cutting-edge technology to deliver precise results, enabling healthcare professionals a rapid and accurate detection of Helicobacter pylori, Salmonella typhi and Vibrio cholerae serogroups O1 and O139.

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

July 7, 2024

Chronic inflammation’s influence on TP53 mutations in leukemia evolution explored in new study

Researchers performed a multi-omics evaluation of HSPCs obtained from individuals with myeloproliferative neoplasms transforming to TP53-related secondary forms of acute myeloid leukemia.

September 7, 2023

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 | Psychedelic Invest

TORONTO, May 29, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new

May 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.